ID
14518
Description
Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids; ODM derived from: https://clinicaltrials.gov/show/NCT00691873
Link
https://clinicaltrials.gov/show/NCT00691873
Keywords
Versions (1)
- 4/19/16 4/19/16 -
Copyright Holder
CC BY-NC 3.0
Uploaded on
April 19, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Asthma NCT00691873
Eligibility Asthma NCT00691873
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
severe asthma
Data type
boolean
Alias
- UMLS CUI [1]
- C0581126
Description
immunotherapy
Data type
boolean
Alias
- UMLS CUI [1]
- C0021083
- UMLS CUI [2]
- C0040223
Description
anaphylactic reaction
Data type
boolean
Alias
- UMLS CUI [1]
- C0002792
Description
upper respiratory tract infection
Data type
boolean
Alias
- UMLS CUI [1]
- C0041912
Similar models
Eligibility Asthma NCT00691873
- StudyEvent: Eligibility
C0040808 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0038317 (UMLS CUI [2])
C0040223 (UMLS CUI [1,2])
C0040223 (UMLS CUI [2])